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Abstract
Background: The efficacy of treating hypercalcemia with bisphosphonate (BP) in patients with
advanced oral cancer has not been fully investigated. This retrospective study evaluated the clinical
course of hypercalcemic patients with and without BP treatment.
Methods: Sixteen hypercalcemic patients, most of whom had uncontrollable locoregional lesions
and lung metastases, were studied. Nine patients had been given BP, and the rest had not.
Results: There were significant differences in age and serum ALT between the BP-treated and -
untreated groups. The first administration of BP effectively and safely decreased the serum calcium
level, but repeated administrations were less effective. Although the patients treated with BP
survived significantly longer than the untreated subjects, the difference of the median was only
about 2 weeks.
Conclusion: The occurrence of hypercalcemia in oral cancer patients apparently implies an
extremely poor prognosis, and long-term survival cannot be expected, even with BP treatment.
Background
Cancer-associated hypercalcemia (CAH) frequently
occurs in patients with advanced oral cancer and indicates
that the patients have entered the terminal stage of the dis-
ease [1]. Increased serum calcium (Ca) levels induce
symptoms in the gastrointestinal, kidney, and central
nervous systems [2], reducing the patients' quality of life
(QOL). Although CAH cannot be adequately resolved
without controlling tumor progression, the administra-
tion of bisphosphonate (BP) has been reported to effec-
tively decrease the serum Ca level, and improve QOL [2-
4]. Especially in the case of patients with a slow-growing
tumor, such as breast cancer, BP can significantly control
pain caused by bone metastasis [5]. Accordingly, BP
administration might be useful to improve the QOL of
CAH patients in whom long-term survival is anticipated.
However, advanced oral cancers usually progress rapidly,
and the average survival time after the occurrence of CAH
is approximately 1 or 2 months [1,6]; thus, BP treatment
might not be helpful for all CAH patients with advanced
oral cancer. However, there have been few reports on the
clinical effects of giving BP to oral cancer patients with
CAH, so its potential usefulness is uncertain.
Here we retrospectively investigated the clinical course of
CAH patients with advanced oral cancer who were or were
not treated for CAH with BP.
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A retrospective analysis was conducted of all patients who
received a diagnosis of hypercalcemia associated with oral
cancer at the Department of Oral and Maxillofacial Sur-
gery of University of Tsukuba Hospital, between 1995 and
2004. Hypercalcemia was defined as a serum Ca level of
higher than 11 mg/dl, which is the upper limit of the nor-
mal range in healthy individuals, in tests performed at the
clinical laboratory. The value for the serum Ca level was
corrected against the value of the serum albumin level [7].
The decision to treat with BP was determined by state of
tumor advancement, symptoms caused by CAH and gen-
eral condition.
Patient characteristics such as the primary tumor site,
stage of tumor progression, general condition, laboratory
test values at the diagnosis of CAH, and the administra-
tion of anti-tumor and anti-CAH agents were determined
by reviewing medical records. The serum Ca levels assayed
before and after the BP administration were examined to
evaluate the effect of the BP treatment. The laboratory
findings from before BP administration were compared
between patients treated with BP (BP group) and those
that did not receive BP (non-BP group). Survival time was
calculated as the period from the occurrence of hypercal-
cemia to death, and the factors influencing the survival
time were evaluated.
The Mann-Whitney test was applied to compare the influ-
ence of age and laboratory findings on the occurrence of
CAH in the BP and non-BP groups. Survival time after the
occurrence of CAH was also analyzed statistically using
the Mann-Whitney test within each set of clinical and lab-
oratory characteristics for all patients. Differences with a p
value of less than 0.05 were considered statistically signif-
icant.
Results
1. Characteristics of patients at the diagnosis of CAH
The 16 subjects were 10 men and 6 women, with CAH
and advanced oral cancer, and their age ranged from 24 to
84 years, with a mean of 60.4 years. The primary sites of
oral cancer were the tongue in 6 patients, the lower gin-
giva in 2, and the maxillary sinus in 2, and 1 each had as
the primary site the floor of mouth, the buccal mucosa,
the upper gingiva, and the oropharynx. Of the remaining
2 patients, one had simultaneously duplicated oral can-
cers of the lower and upper gingivas, and another had
metachronous multiple oral cancers of the lower gingiva,
buccal mucosa, and tongue. The time from the initial
diagnosis of oral cancer to the occurrence of CAH ranged
from 3 to 81 months, with a median of 11.5 months. The
value of parathyroid hormone related protein (PTHrP),
which was measured in 7 patients, ranged from 103 to
475 pmol/l, with a median of 160.4 pmol/l; these values
were higher than the 16.2 to 64.7 pmol/l normal range
found at our hospital.
Of the 16 patients, 12 had uncontrollable head and neck
lesions, lung or pleural metastases were observed in 14
(87.5%), and 7 had bone metastases (43.8%, Table 1).
2. Treatment for CAH
Nine of the 16 patients were treated with BPs for CAH (BP
group). The remaining 7 patients did not undergo a spe-
cific therapy for CAH (non-BP group). On average, the BP
group was significantly younger and showed significantly
lower alanine aminotransferase (ALT) levels than the non-
BP group, but there were no statistical differences in the
other laboratory variables (Table 2).
The BP group received BP in the form of pamidronate (30
mg, 3 patients) or incadronate (10 mg, 6 patients). The
medications were given 1 to 5 times, with a mean of 2.7
times. The median serum Ca level before the initial
administration was 12.9 mg/dl, ranging from 12.2 to 16
mg/dl, and after the administration the median Ca level
decreased to 10.6 mg/dl, ranging from 9.6 to 12.2 mg/dl.
The median amount of decrease was 2.2 mg/dl. The time
from the initiation of treatment to the maximum effect on
Ca levels ranged from 4 to 7 days, with a median of 5 days.
Six patients received two or more treatments, with a
median interval of 14 days. The median decreases in
serum Ca levels after the 2nd and 3rd administrations
were 1.5 mg/dl and 0.7 mg/dl, respectively (Table 3).
Most patients showed improved consciousness in associ-
ation with the decrease of serum Ca level caused by BP
administration. None of the patients showed a serious
adverse effect from the treatment.
3. Survival time after diagnosis of CAH
The serum Ca level measured within 2 days of death
ranged from 9.6 to 15.7 mg/dl, with a mean value of 12.5
mg/dl. Most patients died of respiratory insufficiency
caused by the progression of pulmonary metastases. The
survival time from the diagnosis of CAH in the 16 patients
ranged 3 to 152 days, with a median duration of 31 days.
Table 1: Tumor progression in CAH patients at diagnosis
Lesion Patients (%)
Uncontrollable locoregional lesions 12 (75.0)
Distant metastases
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associated with any of the clinical and laboratory charac-
teristics except the administration of BP: The patients in
the BP group lived significantly longer than those in the
non-BP group (Table 4).
Discussion
CAH is classified as a humoral hypercalcemia of malig-
nancy or local osteolytic types. CAH occurring in patients
with advanced, uncontrollable oral cancer is usually
humoral hypercalcemia, and is associated with a rise in
the PTHrP level [1,6]. In the current study, a rise in the
PTHrP level was observed in all 7 patients in whom the
level was measured, and fewer than half of the patients
had evidence of local bone destruction or bone metasta-
sis. Consequently, in this study the CAH of the patients
was most likely not local osteolytic CAH but humoral
CAH.
The administration of BP for CAH is considered to be a
standard therapy. Pamidronate and incadronate are
reported to induce a decrease in the serum Ca level of
about 2 mg/dl. The time from the initiation of BP admin-
istration to the occurrence of the maximum effect is 4
days, and the effect continues for two weeks [8]. The
present study showed a decrease in the serum Ca level of
about 2 mg/dl after the first administration, a maximal
effect at day 5, and an effective duration of 2 weeks, as pre-
viously reported [8]. Repeated administrations were less
effective, but the usefulness and safety of BP administra-
tion was confirmed for CAH patients with advanced oral
cancer.
The administration of BP has not been indicated for all
patients with CAH. Heath stated that not all patients with
severe hypercalcemia should be treated, and that the deci-
sion should depend on the recent QOL of patients, cur-
rent symptoms, and the prospect of further treatment for
the malignancy [9]. Ling et al. reported that the primary
aim of the treatment should be symptom control, and that
the benefit of the treatment should be questioned for
patients with neither a further indication for anti-cancer
therapy nor symptoms caused by CAH [10]. Lamy et al.
claimed that antihypercalcemic treatment should be
guided by the severity of the hypercalcemia (> 3.00 mM/
L, 12 mg/dl), not by the symptoms [4]. We decided the
Table 3: Serum Ca control with repeated administrations of BP
mean ± s.d. median min. ~max.
1st administration (n = 9)
pre Ca (mg/dl) 13.4 ± 1.2 12.9 12.2 ~16.0
post lowest Ca (mg/dl) 10.7 ± 0.8 10.6 9.6 ~12.2
Ca decrease (mg/dl) 2.7 ± 1.5 2.2 1.6 ~6.1
2nd administration (n = 6)
pre Ca (mg/dl) 13.0 ± 1.2 12.5 11.8 ~14.5
post lowest Ca (mg/dl) 11.4 ± 0.9 11.2 10.5 ~13.0
Ca decrease (mg/dl) 1.6 ± 0.7 1.5 0.7 ~2.7
3rd administration (n = 4)
pre Ca (mg/dl) 13.3 ± 1.1 13.1 11.8 ~14.7
post lowest Ca (mg/dl) 12.8 ± 2.3 11.8 10.7 ~16.0
Ca decrease (mg/dl) 0.5 ± 1.5 0.7 -1.9 ~2.2
Table 2: Comparison of BP-treated and non-BP-treated patient groups
Characteristics BP group (n = 9) non-BP group (n = 7) p value*
median (min.~max.) median (min.~max.)
Age 50(24~73) 76 (58~84) 0.0050
WBC (x1000/m3) 7.1 (6.1~16.4) 8.4 (4.1~35.8) 0.958
Hb (g/dl) 10.3 (7.3~14.5) 11.2 (9.2~14.4) 0.397
Plt (x10000/m3) 32.9 (152~742) 27.8 (192~438) 0.315
AST (IU/dl) 17 (11~87) 26 (13~106) 0.290
ALT (IU/dl) 14 (6~129) 48 (9~267) 0.050
LDH (IU/dl) 173 (112~487) 287 (137~408) 0.596
ALP (IU/dl) 269 (184~721) 322 (171~867) 0.427
Cre (mg/dl) 0.8 (0.5~1.0) 0.8 (0.3~0.9) 0.871
CRP (mg/dl) 3.3 (0.7~19) 4.7 (1.4~13.8) 0.186
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of higher than 12 mg/dl, stages of the tumor progression,
symptoms caused by hypercalcemia and general condi-
tion at the diagnosis of CAH. As the results, there was sig-
nificant difference in age and ALT level between BP and
non-BP groups. The difference in age was probably attrib-
utable to the fact that older patients and their families
often prefer that no further treatment be given at the ter-
minal stage, as they desire an earlier release from the suf-
fering caused by an incurable disease. Younger patients
and their families frequently choose additional interven-
tion, since they wish the patient to have as long a life as
possible. The difference in the ALT level also implies that
the decision to give BP took into consideration the degree
of liver dysfunction.
BP administration has been reported to prolong survival
time [1,6]. The present study also showed a significant
prolongation of survival time in the BP group compared
with the non-BP group, although it was not a randomized
control study and included some bias. As a raised serum
level of PTHrP is reported to indicate a reduced hypocal-
cemic response to BP and an extremely poor prognosis
[11], the anticipated survival time after the occurrence of
CAH is 1 or 2 months in oral cancer, even if BP is given.
CAH patients with oral cancer commonly have uncontrol-
lable locoregional lesions causing serious cosmetic, func-
tional, and social disturbances, which continue to
deteriorate until their death. These disturbances might be
easier to accept with the low level of consciousness caused
by hypercalcemia. Consequently, whether to treat CAH
with BP should be determined individually on the basis of
a patient's physical and mental status and likely survival
time, even if BP administration is effective and safe for
controlling the serum Ca level.
Conclusion
The occurrence of hypercalcemia in oral cancer patients
apparently implies an extremely poor prognosis, and
long-term survival cannot be expected, even with BP treat-
Table 4: Days survived after CAH
Characteristics median (min. ~max.) p value*
Gender
Male (n = 10) 38 (13 ~152) 0.117
Female (n = 6) 22 (3 ~46)
Age
60 > (n = 8) 40.5 (13 ~152) 0.138
60 (n = 8) 27 (3 ~69)
Primary site
Tongue (n = 6) 32 (13 ~46) 0.479
Others (n = 10) 31 (3 ~152)
Time from tumor diagnosis to CAH
Within 1 year (n = 9) 43 (10~152) 0.139
Over 1 year (n = 7) 27 (3~46)
WBC (x 1000/m3) at diagnosis of CAH
10 > (n = 10) 38 (17 ~152) 0.103
10 (n = 6) 20 (3 ~46)
Hb(g/dl) at diagnosis of CAH
10.9 > (n = 8) 41.5 (17 ~152) 0.092
10.9 (n = 8) 22 (3 ~46)
Serum ALP (IU/dl) at diagnosis of CAH
300 > (n = 6) 51 (27 ~152) 0.118
300 (n = 10) 28 (3 ~46)
Serum CRP (mg/dl) at diagnosis of CAH
4.0 > (n = 8) 38.5 (27 ~152) 0.058
4.0 (n = 8) 22 (3 ~46)
Treatment with BP
Yes (n = 9) 44 (13 ~152) 0.015
No (n = 7) 27 (3 ~43)
Treatment with Anticancer agent
Yes (n = 5) 33 (17 ~69) 0.868
No (n = 11) 29 (3 ~152)
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ment. Whether to treat CAH with BP should be deter-
mined individually on the basis of a patient's physical and
mental status and likely survival time.
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